Metallofullerenes: A new class of MRI agents and more?

Nanomedicine

Volumn 8, Issue 11, 2013, Pages 1853-1864

  Fatouros, Panos P ^a   Shultz, Michael D ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

brachytherapy; contrast agent; dual modality imaging; fullerene; lutetium; metallofullerene; MRI; nanoparticle; PET imaging; theranostics

Indexed keywords

DOXORUBICIN; FULLERENE DERIVATIVE; GADOFULLERENE DERIVATIVE; GADOLINIUM; LUTETIUM 177; METAL; METALLOFULLERENE DERIVATIVE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROTON; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90; CONTRAST MEDIUM;

AQUEOUS SOLUTION; BRACHYTHERAPY; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG TARGETING; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PROPERTY; CHEMISTRY; DIAGNOSTIC USE; PROCEDURES;

CONTRAST MEDIA; FULLERENES; MAGNETIC RESONANCE IMAGING;

EID: 84887237204     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.160     Document Type: Review

References (80)

1. Kroto HW, Heath JR, Obrien SC, Curl RF, Smalley RE. C-60- Buckminsterfullerene. Nature 318(6042), 162-163 (1985).
2. Schaefer HE. Nano science: The Science of The Small in Physics, Engineering, Chemistry, Biology and Medicine. Springer-Verlag Berlin Heidelberg, Berlin, Germany, 253-254 (2010).
3. Lu X, Feng L, Akasaka T, Nagase S. Current status and future developments of endohedral metallofullerenes. Chem. Soc. Rev. 41(23), 7723-7760 (2012).
4. Anilkumar P, Lu F, Cao L et al. Fullerenes for applications in biology and medicine. Curr. Med. Chem. 18(14), 2045-2059 (2011).
5. Rodriguez-Fortea A, Balch AL, Poblet JM. Endohedral metallofullerenes: a unique host-guest association. Chem. Soc. Rev. 40(7), 3551-3563 (2011).
6. Rodriguez-Fortea A, Irle S, Poblet JM. Fullerenes: formation, stability, and reactivity. Wires Comput. Mol. Sci. 1(3), 350-367 (2011).
7. Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine 3(2), 201-213 (2008). (Pubitemid 351611856)
8. Dorn HC, Fatouros PP. Endohedral metallofullerenes: applications of a new class of carbonaceous nanomaterials. Nanosci. Nanotech. Lett. 2(2), 65-72 (2010).
9. Braun K, Dunsch L, Pipkorn R et al. Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster- fullerene-conjugate: a new chance in cancer diagnostics. Int. J. Med. Sci. 7(3), 136-146 (2010).
10. Macfarland DK, Walker KL, Lenk RP et al. Hydrochalarones. A novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J. Med. Chem. 51(13), 3681-3683 (2008). (Pubitemid 351956497)
11. Zheng JP, Zhen MM, Wang CR, Shu CY. Recent progress of molecular imaging probes based on gadofullerenes. Chinese J. Anal. Chem. 40(10), 1607-1614 (2012).
12. Mikawa M, Kato H, Okumura M et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconj. Chem. 12(4), 510-514 (2001). (Pubitemid 32704179)
13. Stevenson S, Rice G, Glass T et al. Small-bandgap endohedral metallofullerenes in high yield and purity. Nature 401(6748), 55-57 (1999).
14. Weigle JP, Broome DR. Nephrogenic systemic fbrosis: chronic imaging fndings and review of the medical literature. Skeletal Radiol. 37(5), 457-464 (2008).
15. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest. Radiol. 43(12), 817-828 (2008).
16. 2)](10). J. Am. Chem. Soc. 127(26), 9368-9369 (2005). (Pubitemid 40934740)
17. Toth E, Bolskar RD, Borel A et al. Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc. 127(2), 799-805 (2005). (Pubitemid 40178748)
18. Kratschmer W, Lamb L, Fostiropoulos K, Huffman D. Solid C-60-a new form of carbon. Nature 347(6291), 354-358 (1990).
19. Ge ZX, Duchamp JC, Cai T, Gibson HW, Dorn HC. Purifcation of endohedral trimetallic nitride fullerenes in a single, facile step. J. Am. Chem. Soc. 127(46), 16292-16298 (2005). (Pubitemid 41689260)
20. Cai T, Xu L, Shu C et al. Selective formation of a symmetric Sc3N@C-78 bisadduct: adduct docking controlled by an internal trimetallic nitride cluster. J. Am. Chem. Soc. 130(7), 2136-2137 (2008). (Pubitemid 351287972)
21. Lukoyanova O, Cardona CM, Rivera J et al. 'Open rather than closed' malonate methano-fullerene derivatives. The formation of methanofulleroid adducts of Y3N@C-80. J. Am. Chem. Soc. 129(34), 10423-10430 (2007). (Pubitemid 47330260)
22. Cai T, Ge ZX, Iezzi EB et al. Synthesis and characterization of the frst trimetallic nitride templated pyrrolidino endohedral metallofullerenes. Chem. Commun. 28, 3594-3596 (2005). (Pubitemid 43338634)
23. Cai T, Xu L, Gibson HW et al. Sc3N@C-78: encapsulated cluster regiocontrol of adduct docking on an ellipsoidal metallofullerene sphere. J. Am. Chem. Soc. 129(35), 10795-10800 (2007). (Pubitemid 350067489)
24. Cardona CM, Kitaygorodskiy A, Echegoyen L. Trimetallic nitride endohedral metallofullerenes: reactivity dictated by the encapsulated metal cluster. J. Am. Chem. Soc. 127(29), 10448-10453 (2005). (Pubitemid 41051063)
25. 3N@C-80. Chem. Commun. 25, 2653-2655 (2006).
26. Shu C, Corwin F, Zhang J et al. Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1h relaxivity. Bioconj. Chem. 20(6), 1186-1193 (2009).
27. 2COOH)(8)] (x). J. Phys. Chem. B 110 (31), 15597-15601 (2006).
28. Fatouros P, Corwin F, Chen Z-J et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology 240(3), 756-764 (2006). (Pubitemid 44267332)
29. 80. J. Appl. Phys. 101(9), 09E105-09E105-3 (2007).
30. 3-xN (M = Sc, Sm, Lu). J. Phys. Chem. C 112(15), 5770-5777 (2008).
31. 3N@C-80, detected by low-temperature on-chip SQUID technique. J. Appl. Phys. 109(7), 07B101-07B101-3 (2011).
32. 3N) metallofullerene MRI contrast agents with optimized functionality. Bioconj. Chem. 21(4), 610-615 (2010).
33. Zhang JF, Ge JC, Shultz MD et al. In vitro and in vivo studies of single-walled carbon nanohorns with encapsulated metallofullerenes and exohedrally functionalized quantum dots. Nano Lett. 10(8), 2843-2848 (2010).
34. Brenner IB, Zander AT. Axially and radially viewed inductively coupled plasmas-a critical review. Spectrochim. Acta B 55(8), 1195-1240 (2000).
35. Morishige Y, Kimura A. Ionization interference in inductively coupled plasma-optical emission spectroscopy. Sei Techn. Rev. 66, 106-111 (2008). (Pubitemid 351631687)
36. Sah RN, Brown PH. Boron determination-a review of analytical methods. Microchem. J. 56(3), 285-304 (1997). (Pubitemid 127401804)
37. Sosnovik DE, Caravan P. Molecular MRI of the cardiovascular system in the post-NSF era. Curr. Cardiovasc. Imaging Rep. 6(1), 61-68 (2013).
38. Shultz MD, Wilson JD, Fuller CE, Zhang J, Dorn HC, Fatouros PP. Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology 261(1), 136-143 (2011).
39. Wilson JD, Broaddus WC, Dorn HC, Fatouros PP, Chalfant CE, Shultz MD. Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme. Bioconj. Chem. 23(9), 1873-1880 (2012).
40. Diener MD, Alford JM, Kennel SJ, Mirzadeh S. Pb-212@C-60 and its water-soluble derivatives: synthesis, stability, and suitability for radioimmunotherapy. J. Am. Chem. Soc. 129(16), 5131-5138 (2007). (Pubitemid 46651391)
41. Bethune DS, Johnson RD, Salem JR, Devries MS, Yannoni CS. Atoms in carbon cages-the structure and properties of endohedral fullerenes. Nature 366(6451), 123-128 (1993).
42. Shultz MD, Duchamp JC, Wilson JD et al. Encapsulation of a radiolabeled cluster inside a fullerene cage, (LuxLu(3-x) N)-Lu-177@C-80: an interleukin-13-conjugated radiolabeled metallofullerene platform. J. Am. Chem. Soc. 132(14), 4980-4981 (2010).
43. Diederich F, Thilgen C. Covalent fullerene chemistry. Science 271(5247), 317-323 (1996). (Pubitemid 126554870)
44. Thompson BC, Frechet JMJ. Organic photovoltaics-Polymer-fullerene composite solar cells. Angew. Chem. Int. Ed. Engl. 47(1), 58-77 (2008).
45. Fillmore HL, Shultz MD, Henderson SC et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine (Lond.) 6(3), 449-458 (2011).
46. Li YG, Zhang XD, Li QN, Li WX. Radioiodination of C-60 derivative C-60(OH)(x)O-Y J. Radioanal. Nucl. Chem. 250(2), 363-364 (2001).
47. Wharton T, Wilson LJ. Toward fullerene-based X-ray contrast agents: design and synthesis of non-ionic, highly-iodinated derivatives of C-60. Tetrahedron Lett. 43(4), 561-564 (2002). (Pubitemid 34085013)
48. Chawla P, Chawla V, Maheshwari R, Saraf SA, Saraf SK. Fullerenes: from carbon to nanomedicine. Mini Rev. Med. Chem. 10(8), 662-677 (2010).
49. Partha R, Conyers JL. Biomedical applications of functionalized fullerene-based nanomaterials. Int. J. Nanomedicine. 4, 261-275 (2009).
50. Zhang X, Chibli H, Mielke R, Nadeau J. Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells. Bioconj. Chem. 22(2), 235-243 (2011).
51. Ehrich M, Van Tassell R, Li YB, Zhou ZG, Kepley CL. Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro. Toxicol. In Vitro 25(1), 301-307 (2011).
52. Johnston HJ, Hutchison GR, Christensen FM, Aschberger K, Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol. Sci. 114(2), 162-182 (2010).
53. Levi N, Hantgan RR, Lively MO, Carroll DL, Prasad GL. C60-fullerenes: detection of intracellular photoluminescence and lack of cytotoxic effects. J. Nanobiotechnol. 4, 14 (2006).
54. Roursgaard M, Poulsen SS, Kepley CL, Hammer M, Nielsen GD, Larsen ST. Polyhydroxylated C60 fullerene (fullerenol) attenuates neutrophilic lung infammation in mice. Basic Clin. Pharmacol. Toxicol. 103(4), 386-388 (2008).
55. Tsao N, Kanakamma PP, Luh TY, Chou CK, Lei HY. Inhibition of Escherichia coli-induced meningitis by carboxyfullerence. Antimicrob. Agents Chemother. (9), 2273-2277 (1999). (Pubitemid 29421214)
56. Wang J, Chen C, Li B et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem. Pharmacol. 71(6), 872-881 (2006). (Pubitemid 43208844)
57. 60): lack of lethality after high dose exposure to human epidermal and bacterial cells. Toxicol. Lett. 197(2), 128-134 (2010).
58. Funkhouser J. Reinventing pharma: the theranostic revolution. Curr. Drug Discov. 2, 17-19 (2002). (Pubitemid 34919080)
59. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconj. Chem. 22(10), 1879-1903 (2011).
60. Chen ZY, Ma LJ, Liu Y, Chen CY. Applications of functionalized fullerenes in tumor theranostics. Theranostics 2(3), 238-250 (2012).
61. Allard E, Passirani C, Benoit J P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30(12), 2302-2318 (2009).
62. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas. symposium review. J. Neurooncol 73(1), 57-69 (2005). (Pubitemid 40823269)
63. Meng H, Xing GM, Sun BY et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 4(5), 2773-2783 (2010).
64. Yang D, Zhao YL, Guo H et al. [Gd@C-82(OH)(22)](n) Nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano 4(2), 1178-1186 (2010).
65. Dellinger A, Olson J, Link K et al. Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 15, 7 (2013).
66. Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin. Nucl. Med. 38(2), 141-148 (2008). (Pubitemid 351163195)
67. Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin. Nucl. Med. 39(4), 276-289 (2009).
68. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin. Nucl. Med. 39(5), 308-340 (2009).
69. Even-Sapir E, Keidar Z, Bar-Shalom R. Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin. Nucl. Med. 39(4), 264-275 (2009).
70. Kaufmann PA, Di Carli MF. Hybrid SPECT/CT and PET/CT imaging: the next step in noninvasive cardiac imaging. Semin. Nucl. Med. 39(5), 341-347 (2009).
71. Iezzi EB, Duchamp JC, Fletcher KR, Glass TE, Dorn HC. Lutetium-based trimetallic nitride endohedral metallofullerenes: new contrast agents. Nano Lett. 2(11), 1187-1190 (2002). (Pubitemid 135706493)
72. Wharton T, Wilson LJ. Highly-iodinated fullerene as a contrast agent for X-ray imaging. Bioorgan. Med. Chem. 10(11), 3545-3554 (2002).
73. 124I labeled Gd3N@C80. App. Sci. 2, 465-478 (2012).
74. Catana C, Procissi D, Wu YB et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc. Natl Acad. Sci. USA 105(10), 3705-3710 (2008). (Pubitemid 351723462)
75. Farahani K, Slates R, Shao Y P, Silverman R, Cherry S. Contemporaneous positron emission tomography and MR imaging at 1.5 T. J. Magn. Reson. Im. 9(3), 497-500 (1999). (Pubitemid 29180148)
76. Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14(4), 459-465 (2008). (Pubitemid 351499385)
77. Pichler BJ, Judenhofer MS, Catana C et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J. Nucl. Med. 47(4), 639-647 (2006). (Pubitemid 46768465)
78. Schlemmer HPW, Pichler BJ, Schmand M et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 248(3), 1028-1035 (2008).
79. Shao YP, Cherry SR, Farahani K et al. Simultaneous PET and MR imaging. Phys. Med. Biol. 42(10), 1965-1970 (1997). (Pubitemid 27448997)
80. Jennings LE, Long NJ. 'Two is better than one'-probes for dual-modality molecular imaging. Chem. Commun. (24), 3511-3524 (2009).